|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Similarly, the tacrolimus stable doses in wild-type CYP3A5 rs776746 carriers who had hypertension were higher than those without hypertension (P = 4.10 × 10<sup>-3</sup> ).
|
30861159 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We explored the association between the CYP3A5 (rs776746) gene and hypertension in the Chinese Han population.
|
28448186 |
2017 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Most Black individuals are functional CYP3A5 expressers, and this is a candidate gene for the high incidence of hypertension in Black populations.
|
27334520 |
2016 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes what is known regarding the relationship of CYP3A5 with hypertension, discusses the limitations in present studies, highlights the gaps and directs research to this field.
|
23863802 |
2014 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Angiotensinogen (AGT), G-protein β3-subunit (GNB3) and cytochrome P450 3A5 (CYP3A5) are candidate hypertension susceptibility genes and risk alleles at these loci have been thought to arise owing to human adaptation to climatic changes following the migration out-of-Africa.
|
23324949 |
2013 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
CYP3A4 and CYP3A5 may contribute to salt-sensitive hypertension in human which may act as biomarkers for this disease.
|
24338455 |
2013 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results of this study show that CYP3A5 polymorphisms are associated with the severity and degree of hypertension in kidney transplant recipients receiving calcineurin inhibitors regardless of the time of recording.
|
21851254 |
2011 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the limited sample size, additional studies are necessary to investigate the role of CYP3A5 in the regulation of BP and the pathogenesis of hypertension.
|
21814220 |
2011 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164).
|
19907160 |
2010 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The CYP3A5 genotype was related with blood pressure in the general population, but the effect on the risk for hypertension in pregnancy has not been evaluated.We compared the allele and genotype frequencies of three functional SNPs in the CYP3A5 (rs776746), CYP3A4 (rs2740574), and CYP21A2 (rs6471) genes between pregnant women who developed hypertension (n = 250) or who remained normotensive (control group, n = 250).
|
20617557 |
2010 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
CYP3A5 and ABCB1 genes and hypertension.
|
19290795 |
2009 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, a latitudinal cline was identified both for the allele frequencies of the SNPs associated with hypertension (CYP3A5, AGT, GNB3), as well as for those associated with the ability to taste phenylthiocarbamide (TAS2R38).
|
18248681 |
2008 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension.
|
18496130 |
2008 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP3A5 genotype does not contribute importantly to BP or risk of HTN, but may influence response to calcium channel blockers in populations in which carrier status of two functional alleles is common.
|
17339868 |
2007 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
One-third of the individuals in this cohort were hypertensive (BP > or =140/90 mmHg), and the genotype distribution between normotensive and hypertensive individuals revealed no association between CYP3A5*1 and hypertension after adjustment for age, BMI and gender (odds ratio, 1.02; P=0.92).
|
16822233 |
2006 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.
|
15596575 |
2005 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016).
|
15952872 |
2005 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
LHGDN |
We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.
|
15596575 |
2005 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
LHGDN |
We speculate whether a high CYP3A5 expressor allele frequency among African-Americans may contribute to a high prevalence of sodium-sensitive hypertension in this population.
|
12754175 |
2003 |